Ozempic(R) Offers Superior Reductions in HbA1c and Body Weight...
BAGSVÆRD, Denmark, Sept. 18, 2019 /PRNewswire/ -- Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed:- Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagli...
Authors: LATEST ASIANET NEWS RELEASES